Biotech Values

[DewDiligence]

Bayer Licenses Maxygen’s FVIIa Analog:
#msg-30422488.

This deal, which includes $90M up-front for a drug not even in phase-1, goes a long way toward restoring MAXY’s tarnished reputation on Wall Street, IMO.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”